One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Hutchison China MediTech Limited logo
Hutchison China MediTech Limited HCM
$ 13.95 -2.92%
report update icon

Quarterly report 2022-Q4
added 11-16-2026

Hutchison China MediTech Limited Financial Statements 2025-2011 | HCM

Annual Financial Statements Hutchison China MediTech Limited

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

12 B 12.8 B 12.8 B 11.3 B 21.6 B 20.1 B 15.5 B 17.3 B 20.8 B 843 M - - - - -

Shares

858 M 855 M 850 M 847 M 793 M 698 M 666 M 664 M 617 M 59.7 M - - - - -

Historical Prices

14 15 15.1 13.3 27.2 28.7 23.3 26.1 33.7 12.7 - - - - -

Net Income

457 M 37.7 M 101 M -361 M -195 M -126 M -106 M -74.8 M -26.7 M -43 M 7.99 M 5.37 M 5.92 M 3.64 M 710 K

Revenue

549 M 630 M 838 M 426 M 356 M 228 M 205 M 214 M 241 M 216 M 178 M 91.8 M 46 M 195 M 167 M

Cost of Revenue

336 M 349 M 384 M 311 M 91.6 M 63.5 M 46.2 M 35.3 M 24.8 M 21.7 M 17.3 M - - - -

Gross Profit

212 M 281 M 454 M 115 M 264 M 39.5 M 205 M 214 M 241 M 216 M 67.4 M 19.8 M 23.8 M 96 M 92.8 M

Operating Income

-39.2 M -43.7 M 18.4 M -408 M -328 M -197 M -146 M -92.6 M -53.4 M -46.7 M -9.77 M -18.3 M - - -

Interest Expense

- - 759 K 652 K 592 K 787 K 1.03 M 1.01 M 1.46 M 1.63 M 1.4 M 1.52 M - - -

EBITDA

-25.9 M -31.4 M 26.6 M -399 M -321 M -191 M -141 M -89.1 M -50.8 M -46.7 M -7.76 M -5.92 M -87 K 2.64 M 9.91 M

Operating Expenses

251 M 325 M 435 M 523 M 593 M 236 M 190 M 163 M 119 M 106 M 77.2 M 26.9 M 24.8 M 97.4 M 87.2 M

General and Administrative Expenses

66.7 M 64.3 M 79.8 M 92.2 M 89.3 M 50 M 39.2 M 30.9 M 24 M - 19.6 M 22.6 M 21.3 M 35.7 M -

All numbers in USD currency

Quarterly Income Statement Hutchison China MediTech Limited

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

858 M 857 M 855 M 856 M 850 M 847 M - - - - - - - - - - - - 70.7 K 58.8 K 83.4 K 665 M - - - 664 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

457 M 455 M 37.7 M 25.8 M 101 M 169 M - - - - - - - - - - - - -29 M -31.2 M -24.3 M -19.1 M - - - -11.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

549 M 278 M 630 M 306 M 838 M 533 M - - - - - - - - - - - - 53.3 M 49.3 M 50 M 52.2 M - - - 52.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

336 M 168 M 349 M 36.9 M 384 M 45.4 M - - - - - - - - - - - - 12.7 M 11.7 M 10.6 M 11.3 M - - - 7.85 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

212 M 110 M 281 M 269 M 454 M 487 M - - - - - - - - - - - - 40.7 M 37.7 M 39.4 M 40.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-39.2 M -3.51 M -43.7 M -27.5 M 18.4 M 112 M - - - - - - - - - - - - -38.4 M -35.9 M -36 M -36 M - - - -25 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- 21.6 M - 1.48 M 759 K 224 K - - - - - - - - - - - - 259 K 83 K 428 K 260 K - - - 206 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-25.9 M 2.6 M -31.4 M -21.3 M 26.6 M 115 M - - - - - - - - - - - - -37.2 M -34.7 M -34.8 M -34.8 M - - - -24.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

251 M 114 M 325 M 296 M 435 M 376 M - - - - - - - - - - - - 79.1 M 73.6 M 75.4 M 76.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

66.7 M 27.8 M 64.3 M 30.5 M 79.8 M 41.8 M - - - - - - - - - - - - 8.92 M 11.5 M 8.64 M 10.2 M - - - 7.02 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Hutchison China MediTech Limited HCM
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Hutchison China MediTech Limited plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Trillium Therapeutics Inc. Trillium Therapeutics Inc.
TRIL
- - $ 1.94 B canadaCanada
Urovant Sciences Ltd. Urovant Sciences Ltd.
UROV
- - $ 532 M britainBritain
Acceleron Pharma Inc. Acceleron Pharma Inc.
XLRN
- - $ 10.9 B usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Zogenix, Inc. Zogenix, Inc.
ZGNX
- -4.97 % $ 664 M usaUSA
Yunhong International Yunhong International
ZGYH
- 0.10 % $ 92.2 M chinaChina
ZIOPHARM Oncology, Inc. ZIOPHARM Oncology, Inc.
ZIOP
- -7.58 % $ 264 M usaUSA
Taysha Gene Therapies Taysha Gene Therapies
TSHA
$ 3.99 -0.25 % $ 1.28 B usaUSA
Zentalis Pharmaceuticals Zentalis Pharmaceuticals
ZNTL
$ 1.38 -7.38 % $ 99.2 M usaUSA
Zoetis Zoetis
ZTS
$ 85.52 2.44 % $ 37.9 B usaUSA
Vanda Pharmaceuticals Vanda Pharmaceuticals
VNDA
$ 3.76 -1.44 % $ 222 M usaUSA
Vericel Corporation Vericel Corporation
VCEL
$ 58.63 1.29 % $ 2.95 B usaUSA
Veracyte Veracyte
VCYT
$ 25.54 5.41 % $ 2.01 B usaUSA
VistaGen Therapeutics VistaGen Therapeutics
VTGN
$ 0.2 5.69 % $ 7.61 M usaUSA
Viking Therapeutics Viking Therapeutics
VKTX
$ 26.19 -2.59 % $ 2.95 B usaUSA
Voyager Therapeutics Voyager Therapeutics
VYGR
$ 1.68 10.2 % $ 98.6 M usaUSA
Zai Lab Limited Zai Lab Limited
ZLAB
$ 22.11 -6.03 % $ 24.2 B chinaChina
Verrica Pharmaceuticals Verrica Pharmaceuticals
VRCA
$ 2.9 -7.64 % $ 30.9 M usaUSA
Wave Life Sciences Ltd. Wave Life Sciences Ltd.
WVE
$ 2.77 -2.64 % $ 467 M singaporeSingapore
Zymeworks Zymeworks
ZYME
$ 26.04 0.77 % $ 1.34 B canadaCanada
XBiotech XBiotech
XBIT
$ 1.76 -1.12 % $ 53.7 M usaUSA
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd.
XTLB
$ 1.54 -4.94 % $ 1.04 B israelIsrael
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
VRTX
$ 536.27 0.39 % $ 137 B usaUSA
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 3.15 -35.42 % $ 2.11 M usaUSA
ADMA Biologics ADMA Biologics
ADMA
$ 13.56 -0.51 % $ 3.23 B usaUSA
Exicure Exicure
XCUR
$ 1.08 2.74 % $ 6.8 M usaUSA
Xencor Xencor
XNCR
$ 34.28 -0.64 % $ 2.54 B usaUSA
Cortexyme Cortexyme
CRTX
- -1.05 % $ 67.1 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 3.69 2.36 % $ 809 M britainBritain
Daré Bioscience Daré Bioscience
DARE
$ 0.45 4.92 % $ 5.03 M usaUSA
Fate Therapeutics Fate Therapeutics
FATE
$ 1.05 2.94 % $ 125 M usaUSA
Greenwich LifeSciences Greenwich LifeSciences
GLSI
$ 20.57 10.01 % $ 278 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
$ 95.8 -0.18 % $ 11.5 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
- - $ 5.72 M chinaChina
iBio iBio
IBIO
$ 0.82 9.38 % $ 85.3 M usaUSA
Kodiak Sciences Kodiak Sciences
KOD
$ 97.66 0.89 % $ 5.2 B usaUSA
Karyopharm Therapeutics Karyopharm Therapeutics
KPTI
$ 0.02 -56.5 % $ 219 usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
BioAtla BioAtla
BCAB
$ 1.74 0.64 % $ 102 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
- - $ 3.85 B usaUSA
UroGen Pharma Ltd. UroGen Pharma Ltd.
URGN
$ 29.77 -0.33 % $ 1.43 B israelIsrael
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.46 -4.45 % $ 1.11 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
- - $ 374 usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA